Conatus Pharmaceuticals Inc. (CNAT)

[biotech2010]

CNAT's current market cap is about $150M, they are in multiple Phase 2's for NASH and ready to start a major Cirrhosis Phase 2 in partnership with NVTS.

Tobira was acquired by Allergan for a minimum of $28.35 per share, or $1.13B and this can increase to $1.965B if they meet their goals.

Tobira announced one year results on a Phase 2 NASH study at the same time as their deal with Allergan-the study is going to go for two years.

Based on this CNAT has to be worth at least 3-4X the current market cap today, why it is at $5 is beyond me but I have taken advantage of the buying opportunity.